Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA certification process.
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to Covid funding; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Duration: August 15, 2018
to
present
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Budget/Appropriations , Copyright/Patent/Trademark , Consumer Issues/Safety/Protection
Spending: about $1,340,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Cindy Brown
Leg Assistant, Rep. Stupak, 1993-1994 Leg Director, Rep. Kind, 1999-
2002 Chief of Staff, Rep. Kind, 2003-2009
Jeffrey Forbes
Staff Director, Senate Finance Committee; Chief of Staff, Senator Max
Baucus; Deputy Asst., Special Asst., Deputy Director EOP
Derrick White
Deputy Press Secretary, Senator Orrin Hatch
Jeffrey Strunk
Deputy Floor Director, House Speaker Boehner Floor Assistant, House
Speaker Boehner Legislative Assistant, John Boehner Staff Member,
Pat Tiberi
Libby Greer
Chief of Staff, Rep. Allen Boyd
Francesca McCrary
Legislative Assistant, Elijah Cummings (2016-2017); Professional Staff, House Oversight Reform Committee (2016-2016).
Frank Steinberg
n/a
Jeff Forbes
n/a
Jeff Strunk
n/a
RICHARD LOPEZ
n/a
Adrienne Schweer
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Forbes-Tate lobbied for Walgreens Co. , earning $50,000. The report was filed on April 14.
Original Filing: 301549319.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA certification process.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to Covid funding; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2023
In Q4, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Jan. 16.
Original Filing: 301525916.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA certification process.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to Covid funding; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2023
In Q3, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Oct. 17, 2023.
Original Filing: 301503324.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA certification process.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to Covid funding; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2023
In Q2, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on July 16, 2023.
Original Filing: 301477136.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to FDA certification process.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to Covid funding; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2023
In Q1, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on April 17, 2023.
Original Filing: 301453110.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to FDA certification process.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to Covid funding; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2022
In Q4, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Jan. 17, 2023.
Original Filing: 301428873.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues regarding implementation of the CARES Act (Public Law No: 116-136); Issues related to Covid funding; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to H.R.7213 - Equitable Community Access to Pharmacist Services Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to Covid funding; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to global intangible low taxed income (GILTI) and 163n.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Covid Funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5502/S. 936 - INFORMED Consumers for us; H.R.4521 America COMPETES Act of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2022
In Q3, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Oct. 17, 2022.
Original Filing: 301406276.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues regarding implementation of the CARES Act (Public Law No: 116-136); Issues related to Covid funding; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to Covid funding; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to global intangible low taxed income (GILTI) and 163n.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Covid Funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5502/S. 936 - INFORMED Consumers for us; H.R.4521 America COMPETES Act of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2022
In Q2, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on July 17, 2022.
Original Filing: 301382219.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues regarding implementation of the CARES Act (Public Law No: 116-136); H.R.2471 - Consolidated Appropriations Act, 2022, Issues related to Covid funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; H.R.2471 - Consolidated Appropriations Act, 2022, Issues related to Covid funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to global intangible low taxed income (GILTI) and 163n.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); H.R.2471 - Consolidated Appropriations Act, 2022, Issues related to Covid Funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5502/S. 936 - INFORMED Consumers for us; H.R.4521 America COMPETES Act of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2022
In Q1, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on April 17, 2022.
Original Filing: 301358017.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues regarding implementation of the CARES Act (Public Law No: 116-136); H.R.2471 - Consolidated Appropriations Act, 2022, Issues related to Covid funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; H.R.2471 - Consolidated Appropriations Act, 2022, Issues related to Covid funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to global intangible low taxed income (GILTI).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); H.R.2471 - Consolidated Appropriations Act, 2022, Issues related to Covid Funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5502/S. 936 - INFORMED Consumers for us; H.R.4521 America COMPETES Act of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2021
In Q4, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Jan. 16, 2022.
Original Filing: 301323618.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues regarding implementation of the CARES Act (Public Law No: 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to global intangible low taxed income (GILTI).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5502/S. 936 - INFORMED Consumers for us.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2021
In Q3, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Oct. 18, 2021.
Original Filing: 301302296.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues regarding implementation of the CARES Act (Public Law No: 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to global intangible low taxed income (GILTI).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on July 17, 2021.
Original Filing: 301278582.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues regarding implementation of the CARES Act (Public Law No: 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to global intangible low taxed income (GILTI).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2021
In Q1, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on April 17, 2021.
Original Filing: 301255174.xml
Lobbying Issues
Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues regarding implementation of the CARES Act (Public Law No: 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding implementation of the CARES Act (Public Law No: 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues regarding implementation of the CARES Act (Public Law No: 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding implementation of the CARES Act (Public Law No: 116-136) and the Families First Coronavirus Response Act (Public Law No: 116-127); H.R. 6379 (116th Congress) - Workforce Emergency Response Act of 2020; Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to S. 3431 (116th Congress) - INFORM Consumers Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2020
In Q4, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236616.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding H.R. 748 - the CARES Act (Pub.L. 116-136) and H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116-127); H.R. 6379 - Take Responsibility for Workers and Families Act; Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to S. 3431 - INFORM Consumers Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2020
In Q3, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Oct. 19, 2020.
Original Filing: 301213259.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding H.R. 748 - the CARES Act (Pub.L. 116-136) and H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116-127); H.R. 6379 - Take Responsibility for Workers and Families Act; Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on July 18, 2020.
Original Filing: 301193046.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding H.R. 748 - the CARES Act (Pub.L. 116-136) and H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116-127); H.R. 6379 - Take Responsibility for Workers and Families Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on April 18, 2020.
Original Filing: 301171842.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding H.R. 748 - the CARES Act (Pub.L. 116-136) and H.R. 6201 - Families First Coronavirus Response Act (Pub.L. 116-127); H.R. 6379 - Take Responsibility for Workers and Families Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121466.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement; Issues regarding Section 965 - Treatment of Deferred Foreign Income.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Oct. 19, 2019.
Original Filing: 301072063.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on July 19, 2019.
Original Filing: 301051623.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301035745.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, Forbes-Tate lobbied for Walgreens Co. , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301014259.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, Forbes-Tate lobbied for Walgreens Co. , earning $30,000. The report was filed on Oct. 22, 2018.
Original Filing: 300995810.xml
Lobbying Issues
Issues related to pharmacies and pharmacists, Medicare reimbursement, and opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to pharmacies and pharmacists, and Medicare reimbursement.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Taxation/Internal Revenue Code
3rd Quarter, 2018
Forbes-Tate filed a lobbying registration on Sept. 11, 2018 to represent Walgreens Co., effective Aug. 15, 2018.
Original Filing: 300981654.xml
Issue(s) they said they’d lobby about: Issues related to pharmacies and pharmacists, Medicare reimbursement, drug pricing, and tax. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate